Pharmaceuticals
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology (ASH) Annual Meeting. CS1001-201 trial is a single-arm, multicenter Phase II c...
2019-12-10 11:38
2629
Townsville Hospital Treats First Australian Patient With Elekta Unity MR-Linac, a Transformative Approach to Precision Radiation Therapy
Ability to adapt daily treatment based on real-time MR imaging enables new approach to hard-to-treat cancers TOWNSVILLE, Australia, Dec. 10, 2019 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that Townsville Hospital inQueensland has treated the first patient in Australia using Elekta Unity ...
2019-12-10 08:13
6239
Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies
SUZHOU, China and SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd ("Gracell"), a clinical-stage immune cell therapy company, today announced the progressive clinical outcomes for leading product candidates FasTCAR-19, Dual CAR-19-22, and Dual CAR-BCMA-19 at the American...
2019-12-09 22:00
1357
Hebron Announces $6.5 Million Private Placement
WENZHOU, China, Dec. 9, 2019 /PRNewswire/ -- Hebron Technology Co., Ltd. (" Hebron" or the "Company") (Nasdaq: HEBT), a developer, manufacturer and installer of valves and pipe fittings for use in the pharmaceutical, biological, food and beverage, and other clean industries, today announced that ...
2019-12-09 21:30
2224
BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors
HANGZHOU, China, Dec. 9, 2019 /PRNewswire/ -- BJ Bioscience Inc. (the
'company') today announced that the first patient was successfully dosed on
December 4, 2019 in the first-in-human (FIH) trial of the company's BJ-001
program at NEXT ONCOLOGY inSan Antonio, Texas.
2019-12-09 21:00
1440
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial
SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced the appointment of Ms.Shirley Zhao to the position of General Manager forGreater China and Head of Commercial. In this position, Ms. Zhao will be responsible for the commerci...
2019-12-06 18:53
3706
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China
SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today a...
2019-12-06 08:00
12137
Suvoda Secures $40M Investment from LLR Partners
Growth capital to support expansion of Suvoda's clinical trial software and services CONSHOHOCKEN, Pennsylvania, Dec. 5, 2019 /PRNewswire/ -- Suvoda LLC, a SaaS provider of clinical trial software, announced it secured a$40 million minority equity investment fromPhiladelphia-based private equity...
2019-12-05 17:00
1537
Mayapada Clinic Accomplished Plenary Level Certification from the Accreditation Commission of the Ministry of Health
JAKARTA, Indonesia, Dec. 5, 2019 /PRNewswire/ -- Mayapada Clinic
2019-12-05 13:17
2260
Biocon Biologics Takes Forward its Mission to Unlock Universal Access to Insulins Globally
BUSAN, South Korea, Dec. 5, 2019 /PRNewswire/ -- Biocon Biologics, a fully integrated 'pure play' global biosimilars organisation, is taking forward its mission of unlocking affordable access to quality insulins for people with diabetes across the world. As a credible, global insulins player, it ...
2019-12-05 09:00
1742
FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa
BALERNA, Switzerland, Dec. 4, 2019 /PRNewswire/ -- APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-nam...
2019-12-04 19:22
2471
Merck and Ping An Good Doctor Form Strategic Collaboration to Advance Intelligent Healthcare in China
SHANGHAI, Dec. 4, 2019 /PRNewswire/ -- Merck, a leading science and technology company, signed a strategic collaboration agreement today with one of the world's leading healthcare ecosystem platforms, Ping An Healthcare and Technology Company Limited (Stock code: "Ping An Good Doctor", 1833.HK)....
2019-12-04 12:57
7524
Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection - Lumosa to Initiate the Bridging Study in the US
TAIPEI, Dec. 3, 2019 /PRNewswire/ -- Opioid misuse, addiction, and overdoses have caused significant social and economic burdens leading to the opioid crisis. LT1001 (brand name Naldebain®) is a prodrug of nalbuphine, an abuse-free analgesic that has been marketed worldwide for decades. Naldebain...
2019-12-03 17:36
1078
Continuing the Resplendence with 20 Years' Glory, CPhI China Welcomes the Golden Year of Chinese Pharma
SHANGHAI, Dec. 3, 2019 /PRNewswire/ -- As a world-renowned vertical trade and exchange event of the pharmaceutical industry, CPhI & P-MEC China 2020 will take place at Shanghai New International Expo Centre (SNIEC)June 22-24, 2020. The exhibition will reach a scale of 210,000m2, facilitate over 3...
2019-12-03 16:54
2304
New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority
* NERLYNX® (neratinib) now approved in Singapore for HER2+ breast cancer patients following adjuvant trastuzumab-based therapy * NERLYNX is the first therapy in the Specialised Therapeutics' portfolio approved inSE Asia * Five-year follow up data show NERLYNX reduces risk of invasive disease...
2019-12-03 05:30
1180
Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly
SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics (01801.HK), a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal anti...
2019-12-02 09:37
5250
Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
SUZHOU, China, Dec. 2, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today a...
2019-12-02 08:00
3297
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
SHENZHEN, China, Nov. 29, 2019 /PRNewswire/ -- On November 29, 2019, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Epidaza® (Chidamide), an oral subtype-selective histone deacetylase (HDAC) inhib...
2019-11-29 20:22
4007
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout
HANGZHOU, China and SHAOXING, China, Nov. 29, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Ascle...
2019-11-29 08:00
2638
Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL)
SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced...
2019-11-28 12:10
4416
Week's Top Stories
Most Reposted
Thailand Tops 2024 Consumer Review Awards by Agoda
[Picked up by 329 media titles]
2024-09-26 11:00
WARHAMMER 40,000: SPACE MARINE VR - DEFENDERS OF AVARAX NOW AVAILABLE AT ZERO LATENCY VR VENUES WORLDWIDE
[Picked up by 314 media titles]
2024-09-26 00:00
Advantech Unveils Expanded Singapore Office to Boost ASEAN Presence and Support AIoT Innovations with Strategic Partnerships
[Picked up by 312 media titles]
2024-09-23 13:37
Circles Partners with Telkomsel, Providing an Advanced Software-as-a-Service (SaaS) Platform to Enhance Customer Digital Experience
[Picked up by 297 media titles]
2024-09-27 10:00RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
[Picked up by 294 media titles]
2024-09-23 22:00
Most Read
RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
2024-09-23 22:00
6933
WARHAMMER 40,000: SPACE MARINE VR - DEFENDERS OF AVARAX NOW AVAILABLE AT ZERO LATENCY VR VENUES WORLDWIDE
2024-09-26 00:00
6853
Advantech Unveils Expanded Singapore Office to Boost ASEAN Presence and Support AIoT Innovations with Strategic Partnerships
2024-09-23 13:37
6316
Thailand Tops 2024 Consumer Review Awards by Agoda
2024-09-26 11:00
5639
Sobot Reflects on its Partnership with Lilith Games on Lilith's 11th Anniversary
2024-09-24 10:00
5543
